A retrospective analysis of US medical records of people aged 65-95 years finds those with psoriasis on systemic therapies ...

For patients with psoriasis receiving biologic therapy, residual inflammation (RI), defined as increased inflammatory markers in blood, characterized by high-sensitivity C-reactive protein, despite ...

The study revealed the following findings: 36.3% of psoriasis patients had elevated high-sensitivity C-reactive protein ...

Certain biologic therapies, such as ustekinumab, significantly effect hematological and lipid parameters in patients with psoriasis.

Discover a study in which researchers examined three international cohorts of patients with moderate-to-severe psoriasis ...

Skin symptoms may clear with biologics in psoriasis, but hidden internal inflammation often persists, contributing to major ...

Adults with plaque psoriasis aged 65 years and older had similar responses to IL-17 and IL-23 inhibitors to that of younger adults.

Innovent Biologics doses first participant in phase 3 clinical study of picankibart: San Francisco Friday, May 30, 2025, 12:00 Hrs [IST] Innovent Biologics, Inc, a world-class bio ...

New research shows that in patients with psoriasis, even though their skin responds well to treatment with biologics, ...

A new study reveals psoriasis may increase the risk of obesity and fatty liver despite skin improvements Learn why managing ...

The study reveals that patients with both T2D and psoriasis face a significantly elevated risk of developing renal conditions ...

Inflammation tends to remain in people with psoriasis, despite their skin responding well to treatment with biologics, latest evidence has revealed. Residual inflammation is associated with an ...